Neuropeptide Y receptor

pancreatic polypeptide receptor 1
Identifiers
Symbol	PPYR1
Alt. symbols	NPY4R, Y4, PP1
Entrez	5540
HUGO	9329
OMIM	601790
RefSeq	NM_005972
UniProt	P50391
Other data
Locus	Chr. 10 q11.2

neuropeptide Y receptor Y2
Identifiers
Symbol	NPY2R
Entrez	4887
HUGO	7957
OMIM	162642
RefSeq	NM_000910
UniProt	P49146
Other data
Locus	Chr. 4 q31

neuropeptide Y receptor Y1
Identifiers
Symbol	NPY1R
Alt. symbols	NPYR
Entrez	4886
HUGO	7956
OMIM	162641
RefSeq	NM_000909
UniProt	P25929
Other data
Locus	Chr. 4 q31.3-q32

From Wikipedia, the free encyclopedia

(Redirected from NPY receptor)

Jump to: navigation, search

neuropeptide Y receptor Y5
Identifiers
Symbol	NPY5R
Entrez	4889
HUGO	7958
OMIM	602001
RefSeq	NM_006174
UniProt	Q15761
Other data
Locus	Chr. 4 q31-q32

Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.^[1] These receptors are involved in control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.^[2]^[3]^[4]^[5]^[6]^[7]

Activated neuropeptide receptors release the G_i subunit from the heterotrimeric G protein complex. The G_i subunit in turn inhibits the production of the second messenger cAMP from ATP.

[edit] Types

There are five known mammalian neuropeptide Y receptors designated Y₁ through Y₅.^[8] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.^[9]^[10]^[11]

Y₁ - NPY1R
Y₂ - NPY2R
Y₄ - PPYR1
Y₅ - NPY5R

[edit] References

^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. http://pharmrev.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9549761.
^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373.
^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800.
^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0002R.SGM.
^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213. http://www.bentham-direct.org/pages/content.php?PRN/2006/00000001/00000003/0008PRN.SGM.
^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0008R.SGM.
^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.
^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367.
^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.
^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0009R.SGM.
^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0010R.SGM.

[edit] External links

"Neuropeptide Y Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. http://www.iuphar-db.org/GPCR/ChapterMenuForward?chapterID=1292.
MeSH Neuropeptide+Y+Receptor

This transmembrane receptor-related article is a stub. You can help Wikipedia by expanding it.

[pmid9549761-0] Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. http://pharmrev.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9549761.

[pmid15337373-1] Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373.

[pmid16738800-2] Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800.

[pmid17979774-3] Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0002R.SGM.

[pmid18221213-4] Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213. http://www.bentham-direct.org/pages/content.php?PRN/2006/00000001/00000003/0008PRN.SGM.

[pmid17979780-5] Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0008R.SGM.

[pmid18725086-6] Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.

[pmid15337367-7] Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367.

[pmid17785427-8] Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.

[pmid17979781-9] MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0009R.SGM.

[pmid17979782-10] Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782. http://www.bentham-direct.org/pages/content.php?CTMC/2007/00000007/00000017/0010R.SGM.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

Neuropeptide Y receptor

[edit] Types

[edit] References

[edit] External links

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Interaction

Toolbox

Print/export

Languages